Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Venderova, Katerina, et al.
Movement Disorders. 2004 Sep, 19(9): 1102-1106 (abstract).
Cannabis, cannabinoids and reproduction. Park, Boram, et al.
Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004, 70: 189-197.
Cannabis for dyskinesia in Parkinson’s disease. A randomized double-blind crossover study. Carroll, C B, et al.
Neurology. 2004 Oct 12, 63(7): 1245-1250 (abstract).
Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Avraham, Y, et al. Pharmacology Bioche
mistry and Behavior. 2004 Apr, 77(4): 675-684 (abstract).
Medicinal cannabis: rational guidelines for dosing. Carter, Gregory T, et al.
Drugs. 2004 May 7(5): 464-470.
Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Russo, E B
Neuroendocrinology Letters. 2004 Feb-Apr, 25(1-2): 31-39 (abstract).
Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. Narishetty, Sunil Thomas Kumar, et al.
Journal of Controlled Release. 2004 Mar 24, 95(3): 367-379 (abstract).